MedTrace Logo

Structural and Functional Connectivity of Brainstem Monoamine Pathways in Treatment Resistant Depression

NCT03109717 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 11

Last updated 2021-06-18

No results posted yet for this study

Summary

Study TRD subjects' resistance to at least 2 different antidepressants, we hypothesize that because of their significant depression and treatment resistant status they are most likely to exhibit BSMN pathway abnormalities.

Conditions

Interventions

DRUG

Monoamine Oxidase Inhibitor (MAOI)

Monoamine Oxidase Inhibitor

Sponsors & Collaborators

  • Kathryn O'Connor

    lead OTHER

Principal Investigators

  • Amit Anand, MD · The Cleveland Clinic

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2020-11-30
Completion
2021-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03109717 on ClinicalTrials.gov